Immunovant (IMVT) Projected to Post Earnings on Thursday

Immunovant (NASDAQ:IMVT - Get Free Report) is anticipated to post its Q4 2025 quarterly earnings results before the market opens on Thursday, May 29th. Analysts expect Immunovant to post earnings of ($0.72) per share for the quarter.

Immunovant (NASDAQ:IMVT - Get Free Report) last released its earnings results on Thursday, May 29th. The company reported ($0.64) EPS for the quarter, beating analysts' consensus estimates of ($0.72) by $0.08. The firm had revenue of $0.16 million during the quarter. During the same period in the previous year, the firm posted ($0.52) EPS. On average, analysts expect Immunovant to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Immunovant Stock Performance

Shares of IMVT traded down $0.02 on Friday, reaching $14.87. The stock had a trading volume of 1,456,909 shares, compared to its average volume of 1,198,648. The firm has a market capitalization of $2.53 billion, a price-to-earnings ratio of -5.68 and a beta of 0.75. The company has a 50-day simple moving average of $14.99 and a 200-day simple moving average of $20.38. Immunovant has a 12-month low of $12.72 and a 12-month high of $34.47.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Bank of America lowered their target price on Immunovant from $38.00 to $33.00 and set a "buy" rating for the company in a research note on Thursday, March 20th. Cantor Fitzgerald upgraded Immunovant to a "strong-buy" rating in a research note on Tuesday, March 4th. HC Wainwright restated a "buy" rating and issued a $51.00 target price on shares of Immunovant in a research note on Wednesday, March 19th. Jefferies Financial Group began coverage on Immunovant in a research report on Monday, March 3rd. They set a "hold" rating and a $20.00 price objective for the company. Finally, Guggenheim reaffirmed a "buy" rating on shares of Immunovant in a research report on Thursday, March 20th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $38.33.

Insider Activity at Immunovant

In other Immunovant news, insider Michael Geffner sold 2,349 shares of Immunovant stock in a transaction on Wednesday, April 23rd. The stock was sold at an average price of $14.79, for a total value of $34,741.71. Following the completion of the sale, the insider now owns 225,370 shares of the company's stock, valued at approximately $3,333,222.30. This trade represents a 1.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Andrew J. Fromkin sold 8,000 shares of Immunovant stock in a transaction on Friday, March 7th. The stock was sold at an average price of $19.60, for a total value of $156,800.00. Following the completion of the sale, the director now directly owns 91,913 shares of the company's stock, valued at approximately $1,801,494.80. The trade was a 8.01% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 51,682 shares of company stock valued at $753,419 in the last 90 days. Corporate insiders own 5.90% of the company's stock.

Institutional Trading of Immunovant

Institutional investors and hedge funds have recently modified their holdings of the business. Goldman Sachs Group Inc. increased its holdings in shares of Immunovant by 48.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,007,700 shares of the company's stock worth $17,222,000 after purchasing an additional 329,354 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Immunovant by 8.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,971 shares of the company's stock worth $708,000 after purchasing an additional 3,348 shares in the last quarter. Finally, Strs Ohio bought a new stake in shares of Immunovant in the 1st quarter worth $27,000. Institutional investors own 47.08% of the company's stock.

About Immunovant

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.